Novartis CEO to lead top U.S. pharma lobby
Robert Way/iStock Editorial via Getty Images


The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Wednesday that Vas Narasimhan, Chief Executive of Novartis (NYSE:NVS) (OTCPK:NVSEF), assumed duties as the chair of the industry lobbyâs director board.
Narasimhan replaces Ramona Sequeira, president of Takedaâs (TAK) Global Portfolio Division, who served as PhRMA board chair since February 2022.

âIâm eager to help lead the association at this pivotal moment for patients and our industry,â Narasimhan, who has led the Swiss pharma giant since 2018, said.
Additionally, PhRMA announced that Daniel OâDay, the Chairman and CEO of Gilead Sciences (GILD), will serve as its board chair-elect, and Albert Bourla, the Chairman and CEO of Pfizer (PFE), will become its treasurer.
PhRMA was in the news recently as Teva Pharmaceutical (TEVA) left the influential industry trade group following a similar move by AbbVie (ABBV) late last year.